Soft tissue sarcomas: new opportunity of treatment with PARP inhibitors?
- 54 Downloads
Poly(ADP-ribose) polymerases (PARP) are a large family of enzymes involved in several cellular processes, including DNA single-strand break repair via the base-excision repair pathway. PARP inhibitors exert antitumor activity by both catalytic PARP inhibition and PARP–DNA trapping, moreover PARP inhibition represents a potential synthetic lethal approach against cancers with specific DNA-repair defects. Soft tissue sarcoma (STSs) are a heterogeneous group of mesenchymal tumors with locally destructive growth, high risk of recurrence and distant metastasis.
The purpuse of this review is to provide an overview of the main preclinical and clinical data on use of PARPi in STSs and of effect and safety of combination of PARPi with irradiation.
Due to numerous genomic alterations in STSs, the DNA damage response pathway can offer an interesting target for biologic therapy. Preclinical and clinical studies showed promising results, with the most robust evidences of PARPi efficacy obtained on Ewing sarcoma bearing EWS–FLI1 or EWS–ERG genomic fusions. The activity of PARP inhibitors resulted potentiated by chemotherapy and radiation. Although mechanisms of synergisms are not completely known, combination of radiation therapy and PARP inhibitors exerts antitumor effect by accumulation of unrepaired DNA damage, arrest in G2/M, activity both on oxic and hypoxic cells, reoxygenation by effect on vessels and promotion of senescence. Early trials have shown a good tolerance profile.
The use of PARP inhibitors in advanced stage STSs, alone or combined in multimodal treatments, is of great interest and warrants further investigations.
KeywordsPoly(ADP-ribose) polymerases (PARP) Soft tissue sarcoma (STSs) DNA damage response pathway Radiation therapy
Compliance with ethical standards
Conflicts of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 10.Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (2012) World Health Organization Classification of tumours of soft tissue and bone, vol 5, 4th edn. International Agency for Research on Cancer (IARC) 2013, Lyon, p 468Google Scholar
- 35.Grignani G, D’Ambrosio L, Pignochino Y et al (2016) A phase 1b trial with the combination of trabectedin and olaparib in relapsed patients (pts) with advanced and unresectable bone and soft tissue sarcomas (BSTS): an Italian sarcoma group (ISG) study. J Clin Oncol 34(15S):11018Google Scholar
- 47.Vormoor B, Wilkinson S, Harvey F, et al. (2012) Ewing’s sarcoma cells can be sensitized to temozolomide and to a lesser extent to radiotherapy by co-treatment with a PARP-inhibitor (AG014699). Eur J Cancer 48 (S6):106–107;349Google Scholar
- 50.Kleinberg L, Supko JG, Mikkelsen T et al (2013) Phase I adult brain tumor consortium (ABTC) trial of ABT-888 (veliparib), temozolomide (TMZ), and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM) including pharmacokinetic (PK) data. J Clin Oncol 31(15S):2065Google Scholar
- 52.Jagsi R, Grifth KA, Bellon JR et al (2015) TBCRC 024 Initial results: a multicenter phase 1 study of veliparib administered concurrently with chest wall and nodal radiation therapy in patients with inflammatory or locoregionally recurrent breast cancer. Int J Radiat Oncol Biol Phys 93:S137CrossRefGoogle Scholar
- 53.Reiss KA, Herman JM, Armstrong D et al (2017) A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. Gynecol Oncol 144(3):486–490CrossRefPubMedPubMedCentralGoogle Scholar